查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602405

愛迪生氏症藥物市場：按藥物類別、診斷、治療方法、通路、給藥途徑分類 - 2025-2030 年全球預測

Addison's Disease Treatment Market by Drug Class (Glucocorticoid, Mineralocorticoid), Diagnosis (Imaging Testing, Laboratory Testing), Treatments, Distribution Channel, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

愛迪生氏症治療藥物市場2023年估值為14.1億美元，預計2024年將達到15.4億美元，複合年成長率為10.72%，預計到2030年將達到28.8億美元。

愛迪生氏症是一種罕見的內分泌疾病，其特徵是腎上腺產生荷爾蒙的缺陷，為藥物治療創造了一個利基但重要的市場。由於這種疾病的慢性性質以及荷爾蒙補充療法在預防危及生命的腎上腺危象方面的重要作用，因此需要有效的治療。目前，主要用途是皮​​膚類固醇和鹽皮質激素替代療法，由於患者意識的提高和遠距遠端醫療的進步，最終用途在醫院、專科診所和居家醫療環境中獲得了顯著的吸引力。腎上腺功能不全疾病盛行率上升、診斷技術的改進以及高風險老年人口的增加等因素推動了市場成長。有開發新型遞送機制的機會，例如植入式裝置和緩釋性，以提高患者的依從性和生活品質。此外，基因治療和生物治療的研究正在取得進展，有潛力提供差異化治療。然而，限制因素包括高昂的研發成本、長期使用類固醇的潛在副作用，以及減緩新產品進入的嚴格監管核准流程。此外，提高醫療專業人員的意識提升，提高早期診斷和治療的準確性也是一個問題。使用基因檢測和人工智慧驅動的患者管理系統的個人化醫療創新有可能顯著改善治療結果和市場定位。對於業務成長，與研究機構的策略聯盟以及對生物資訊學的投資可以提供競爭優勢。作為一個競爭激烈且高度專業化的市場，成功需要科學的專業知識和以患者為中心的方法。實施數位醫療解決方案和促進強力的病患教育舉措是應對不斷變化的情況和利用新機會的策略措施。

主要市場統計
基準年[2023] 14.1億美元
預測年份 [2024] 15.4億美元
預測年份 [2030] 28.8億美元
複合年成長率（%） 10.72%

市場動態：快速發展的愛迪生氏症藥物市場的關鍵市場洞察

愛迪生氏症藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球愛迪生氏症症患者數量增加
    • 人們對腎上腺功能不全的認知不斷提高
    • 建立堅實的醫療基礎設施和優惠的報銷政策
  • 市場限制因素
    • 艾迪生療法相關的高成本
  • 市場機會
    • 對新一代技術整合先進療法的需求不斷成長
    • 活性化研發活動並提高各公司對愛迪生氏症藥物開發的關注度
  • 市場挑戰
    • 人們對愛迪生氏症缺乏認知

波特五力：駕馭愛迪生氏症藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解愛迪生氏症藥物市場的外部影響

外部宏觀環境因素在塑造愛迪生氏症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解愛迪生氏症治療藥物市場的競爭狀況

對愛迪生氏症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

愛迪生氏症治療藥物市場中的 FPNV 定位矩陣供應商績效評估

FPNV 定位矩陣是評估愛迪生氏症治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為愛迪生氏症治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對愛迪生氏症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球愛迪生氏症發生率上升
      • 人們對腎上腺功能不全的認知不斷增強
      • 引入強大的醫療基礎設施和優惠的報銷政策
    • 抑制因素
      • 艾迪生治療相關的高成本
    • 機會
      • 對整合技術的新一代先進療法的需求不斷成長
      • 增加企業研發活動並專注於開發愛迪生氏症治療方法
    • 任務
      • 人們對愛迪生氏症缺乏認知
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的愛迪生氏症治療藥物市場

  • 糖皮質激素
    • 地塞米松
    • Hydrocortisone
    • 強的松
  • 鹽皮質激素
    • ludrocortisone

第7章 依診斷分類的愛迪生氏症治療藥物市場

  • 影像檢查
  • 臨床檢查

第8章愛迪生氏症治療藥物市場（依治療）

  • 皮質類固醇注射
  • 自然療法解決方案
  • 口服類固醇

第9章愛迪生氏症治療藥物市場：按分銷管道

  • 電子商務
  • 醫院藥房
  • 零售藥房

第 10 章愛迪生氏症治療藥物市場：依給藥途徑

  • 口服
  • 監護人

第11章 美洲愛迪生氏症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區愛迪生氏症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲愛迪生氏症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Actiza Pharmaceutical Private Limited
  • Akorn Operating Company LLC
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Bay Biosciences LLC
  • Bayer AG
  • Bio-Techne Corporation
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • BTL Biotechno Labs Pvt Ltd.
  • Cardinal Health, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • LUMITOS AG
  • Lupin Limited
  • Merck KGaA
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Recipharm AB
  • Sandoz International GmbH
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-B16853776F01

The Addison's Disease Treatment Market was valued at USD 1.41 billion in 2023, expected to reach USD 1.54 billion in 2024, and is projected to grow at a CAGR of 10.72%, to USD 2.88 billion by 2030.

Addison's Disease, a rare endocrine disorder characterized by insufficient production of hormones by adrenal glands, creates a niche yet vital market for pharmaceutical treatments. The necessity for effective treatments arises from the disease's chronic nature and the essential role of hormone replacement therapies in preventing life-threatening adrenal crises. Currently, primary applications focus on corticosteroid and mineralocorticoid replacement therapies, with end-use finding significant traction in hospitals, specialty clinics, and home care settings, thanks to increasing patient awareness and advancements in telemedicine. Market growth is driven by factors such as rising prevalence of adrenal insufficiency disorders, improved diagnostic techniques, and a larger aged population at higher risk. Opportunities lie in the development of novel delivery mechanisms, such as implantable devices or extended-release formulations, improving patient compliance and quality of life. Additionally, ongoing research into genetic and biologic therapies presents an avenue for differentiated treatment offerings. However, the market faces limitations such as the high cost of R&D, potential side effects of long-term steroid use, and stringent regulatory approval processes that could delay new entrants. Challenges also include the need for increased awareness among healthcare providers for early diagnosis and treatment precision. Innovation in personalized medicine, leveraging genetic testing and AI-driven patient management systems, could significantly enhance treatment outcomes and market positioning. For business growth, strategic partnerships with research institutes and investment in bioinformatics may provide a competitive advantage. The nature of the Addison's Disease treatment market is competitive yet highly specialized, requiring strong scientific expertise and patient-centric approaches to succeed. Embracing digital health solutions and cultivating robust patient education initiatives stand out as strategic maneuvers to navigate the evolving landscape and capitalize on emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 1.41 billion
Estimated Year [2024] USD 1.54 billion
Forecast Year [2030] USD 2.88 billion
CAGR (%) 10.72%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Addison's Disease Treatment Market

The Addison's Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of Addison's disease globally
    • Growing awareness regarding adrenal insufficiency
    • Inception of robust healthcare infrastructure and favorable reimbursement policies
  • Market Restraints
    • High costs associated with the Addison treatment medications
  • Market Opportunities
    • Growing demand for new generation technologically integrated advanced therapeutic drugs
    • Increasing R&D activities and rising focus of the companies in developing treatments for Addison's disease
  • Market Challenges
    • Lack of awareness among people regarding Addison's disease

Porter's Five Forces: A Strategic Tool for Navigating the Addison's Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Addison's Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Addison's Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Addison's Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Addison's Disease Treatment Market

A detailed market share analysis in the Addison's Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Addison's Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Addison's Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Addison's Disease Treatment Market

A strategic analysis of the Addison's Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Addison's Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Actiza Pharmaceutical Private Limited, Akorn Operating Company LLC, Amgen Inc., Amneal Pharmaceuticals, Inc., Bay Biosciences LLC, Bayer AG, Bio-Techne Corporation, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, BTL Biotechno Labs Pvt Ltd., Cardinal Health, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, LUMITOS AG, Lupin Limited, Merck KGaA, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Recipharm AB, Sandoz International GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Addison's Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Glucocorticoid and Mineralocorticoid. The Glucocorticoid is further studied across Dexamethasone, Hydrocortisone, and Prednisone. The Mineralocorticoid is further studied across Fludrocortisone.
  • Based on Diagnosis, market is studied across Imaging Testing and Laboratory Testing.
  • Based on Treatments, market is studied across Corticosteroid Injections, Naturopathic Solutions, and Oral Corticosteroids.
  • Based on Distribution Channel, market is studied across E-Commerce, Hospital Pharmacy, and Retail Pharmacy.
  • Based on Route of Administration, market is studied across Oral and Parental.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of Addison's disease globally
      • 5.1.1.2. Growing awareness regarding adrenal insufficiency
      • 5.1.1.3. Inception of robust healthcare infrastructure and favorable reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the Addison treatment medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for new generation technologically integrated advanced therapeutic drugs
      • 5.1.3.2. Increasing R&D activities and rising focus of the companies in developing treatments for Addison's disease
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness among people regarding Addison's disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Addison's Disease Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Glucocorticoid
    • 6.2.1. Dexamethasone
    • 6.2.2. Hydrocortisone
    • 6.2.3. Prednisone
  • 6.3. Mineralocorticoid
    • 6.3.1. Fludrocortisone

7. Addison's Disease Treatment Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Imaging Testing
  • 7.3. Laboratory Testing

8. Addison's Disease Treatment Market, by Treatments

  • 8.1. Introduction
  • 8.2. Corticosteroid Injections
  • 8.3. Naturopathic Solutions
  • 8.4. Oral Corticosteroids

9. Addison's Disease Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. E-Commerce
  • 9.3. Hospital Pharmacy
  • 9.4. Retail Pharmacy

10. Addison's Disease Treatment Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Oral
  • 10.3. Parental

11. Americas Addison's Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Addison's Disease Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Addison's Disease Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Actiza Pharmaceutical Private Limited
  • 3. Akorn Operating Company LLC
  • 4. Amgen Inc.
  • 5. Amneal Pharmaceuticals, Inc.
  • 6. Bay Biosciences LLC
  • 7. Bayer AG
  • 8. Bio-Techne Corporation
  • 9. Biogen Inc.
  • 10. Boehringer Ingelheim International GmbH
  • 11. Bristol-Myers Squibb Company
  • 12. BTL Biotechno Labs Pvt Ltd.
  • 13. Cardinal Health, Inc.
  • 14. Eli Lilly and Company
  • 15. GlaxoSmithKline PLC
  • 16. Hikma Pharmaceuticals PLC
  • 17. LUMITOS AG
  • 18. Lupin Limited
  • 19. Merck KGaA
  • 20. Neurocrine Biosciences, Inc.
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. Recipharm AB
  • 24. Sandoz International GmbH
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ADDISON'S DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ADDISON'S DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ADDISON'S DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ADDISON'S DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADDISON'S DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADDISON'S DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY FLUDROCORTISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY IMAGING TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY NATUROPATHIC SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 147. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 154. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 155. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 161. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 162. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 174. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 176. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 177. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 183. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 184. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 190. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 191. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 197. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 198. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 204. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 205. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 211. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 212. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 218. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 219. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 225. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 226. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 232. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 233. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 238. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 239. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 240. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 245. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 246. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 247. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 252. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 253. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 254. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 259. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 260. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 261. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 266. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 267. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 268. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 273. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 274. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 281. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 282. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 287. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 288. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 289. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 293. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 294. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 295. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 296. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 301. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 302. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 303. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 304. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 307. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 308. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 309. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 310. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED KINGDOM